Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:6166 |
Name | prostatic urethra urothelial carcinoma |
Definition | |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer urinary system cancer urethra cancer male urethral cancer prostatic urethral cancer prostatic urethra urothelial carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00794950 | Phase II | Sunitinib | Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma | Completed | USA | 0 |
NCT01688999 | Phase II | Cabozantinib | Cabozantinib for Advanced Urothelial Cancer | Completed | USA | 0 |
NCT03106610 | Phase I | Nivolumab | Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy | Terminated | USA | 0 |
NCT03549715 | Phase Ib/II | Cisplatin + Doxorubicin + Durvalumab + Methotrexate + Tremelimumab + Vinblastine Cisplatin + Doxorubicin + Durvalumab + Methotrexate + Vinblastine | NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma (NEMIO) | Active, not recruiting | FRA | 0 |
NCT04506554 | Phase II | Cisplatin + Doxorubicin + Methotrexate + Nivolumab + Vinblastine | A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer | Active, not recruiting | USA | 0 |